AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29908336
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) with praise and financial incentives targeted at abstinence from opiates or attendance at treatment sessions
Trial: 27737664
Drug: etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 60 mg (escalated to 90 mg)
Trial: 27737664
Drug: etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 90 mg (continued)
Trial: 27737664
Drug: naproxen 1000
RxNorm normalized name: naproxen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 1000 mg (continued)
Trial: 16791612
Drug: Topical hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hydrocortisone (HC)
Trial: 16791612
Drug: Topical hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hydrocortisone (HC) with physiotherapy (PT)
Trial: 12659547
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (pharmacotherapy and psychodynamic supportive psychotherapy)
Trial: 9189727
Drug: Normal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal diet (NORM) for 3 days, 426 (137) g.day‐1 CHO [5.9 (1.4) g.kg‐1 body mass (BM)]
Trial: 9189727
Drug: Additional carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional carbohydrate (SUPP) for 3 days, 661 (76) g.day‐1 CHO [9.3 (0.7) g.kg‐1 BM]
Trial: 3104123
Drug: Transdermal Therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Therapeutic System releasing 10 mg of nitroglycerin over 24 hours (TTS 10)
Trial: 3104123
Drug: Sublingual isosorbide
RxNorm normalized name: isosorbide dinitrate Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual isosorbide dinitrate 5 mg (ISDN)
Trial: 26122982
Drug: Intervention package
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention package delivered by community midwives including psychoeducation, problem solving treatment, and parenting skills, with clinical support via mobile phone.
Trial: 26122982
Drug: Care as
RxNorm normalized name: TopCare Aspirin 325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care as usual enhanced by further training of providers in recognition and standard treatment of depression.
Trial: 20512335
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (GJ) consumed 200 mL three times a day for three days prior to PK analysis.
Trial: 7910880
Drug: Regular salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular salbutamol (2 puffs - 200 micrograms - four times daily)
Trial: 20193095
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (10 microg daily)
Trial: 20193095
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (10 microg daily) + Calcium (600 mg daily)
Trial: 20193095
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient (including 10 microg Vitamin D) + Calcium (600 mg daily)
Trial: 16511419
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (brief physician advice, self-help materials, nicotine replacement therapy)
Trial: 8838965
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin (5 g loading dose, intravenous infusion twice, 4 h apart)
Trial: 6342752
Drug: Primary radiation
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary radiation therapy
Trial: 9748717
Drug: Cefdinir 100
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 100 mg capsule (Cefzon)
Trial: 9748717
Drug: Cefdinir 100
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 100 mg daily for 3 to 8 days
Trial: 9748717
Drug: Cefdinir 200
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 200 mg (2 capsules) daily for 4 to 14 consecutive days
Trial: 2971515
Drug: salbutamol, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol, 5 mg mixed with ipratropium bromide 500 micrograms
Trial: 2971515
Drug: salbutamol, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol, 5 mg
Trial: 12402423
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IL-2 and IFN-alpha
Trial: 12402423
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of other cytokines (e.g., GM-CSF) or chemotherapy
Trial: 29656500
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (TRT) for six months
Trial: 21638162
Drug: Aquamid® filler,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquamid® filler, 8 ml per session, retreated every 8 weeks until full correction observed.
Trial: 21638162
Drug: Aquamid® filler,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquamid® filler, 2 ml per session, retreated every 8 weeks until full correction observed.
Trial: 18813866
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of Shoyu polysaccharides (SPS) daily for 2 weeks
Trial: 18813866
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of Shoyu polysaccharides (SPS) daily for 4 weeks
Trial: 10622347
Drug: Amisulpride 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride 800 mg
Trial: 1952008
Drug: Topical glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glyceryl trinitrate ointment
Trial: 1952008
Drug: Eutectic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eutectic mixture of local anaesthetics cream
Trial: 31687933
Drug: Novel paclitaxel-coated
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Novel paclitaxel-coated drug-coated balloon (DCB)
Trial: 29855986
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761 (120 mg, twice a day)
Trial: 24794703
Drug: Insulin analogues
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin analogues (detemir and aspart)
Trial: 24794703
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (human neutral protamine Hagedorn and human regular)
Trial: 22045363
Drug: Midodrine (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (alpha agonist)
Trial: 19551459
Drug: Lactose-[(13)C]ureide breath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-[(13)C]ureide breath test (LUBT) with 2 g of lactose-[(13)C]ureide
Trial: 19551459
Drug: Glucose hydrogen
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose hydrogen breath test (GHBT) with 50 g glucose
Trial: 8602384
Drug: Nephrotoxic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nephrotoxic chemotherapy
Trial: 8602384
Drug: Nonnephrotoxic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonnephrotoxic chemotherapy
Trial: 8602384
Drug: Age effect
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age effect on pharmacokinetics
Trial: 8602384
Drug: Gentamicin dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin dosing
Trial: 2669222
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose nebulised morphine (5 ml of morphine 1 mg/ml)
Trial: 769773
Drug: Active electrosleep
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active electrosleep therapy
Trial: 769773
Drug: Simulated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated treatment (placebo)
Trial: 26081587
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of telmisartan
Trial: 21528641
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of mosapride citrate
Trial: 21528641
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of mosapride citrate
Trial: 8493803
Drug: Amino‐Mel hepa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino‐Mel hepa + L‐valine (Group B)
Trial: 27662264
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral liquid formulation combining guaifenesin, pseudoephedrine and hydrocodone
Trial: 27662264
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral liquid formulation (5 to 15 mL)
Trial: 27662264
Drug: Multiple dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dosing of oral liquid formulation
Trial: 27662264
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral liquid formulation
Trial: 23092665
Drug: Intravenous PPI
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PPI followed by oral administration (group 2)
Trial: 23092665
Drug: Oral PPIs
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PPIs alone (group 1)
Trial: 20021657
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate (AS) 2-5 mg/kg
Trial: 20021657
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate (AS)
Trial: 20021657
Drug: High-fat and
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat and high-caloric meal prior to drug administration
Trial: 18030711
Drug: Therapeutic angiogenesis
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic angiogenesis (cell transplantation, gene therapy, application of growth factors)
Trial: 10924866
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 1000 or 3000 mg
Trial: 8810671
Drug: Reumalex, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reumalex, a licensed over-the-counter herbal medicine
Trial: 1605451
Drug: Defibrotide (DF)
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide (DF) 400 mg i.v. given one hour prior to operation and twice daily for seven days postoperatively
Trial: 1605451
Drug: Calcium-heparin (CH)
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-heparin (CH) 0.2 ml (5000 U.I.) subcutaneously given one hour prior to operation and twice daily for seven days postoperatively
Trial: 1605451
Drug: Calcium-heparin (CH)
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-heparin (CH)
Trial: 6420352
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release buccal nitroglycerin (23.4 mg daily)
Trial: 3716918
Drug: Four hypnotic
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four hypnotic sessions with a booster
Trial: 3716918
Drug: Two hypnotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two hypnotic sessions
Trial: 3716918
Drug: Two hypnotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two hypnotic and two behavioral sessions with a booster
Trial: 3716918
Drug: Four hypnotic
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four hypnotic sessions and a booster session (follow-up group)
Trial: 25708324
Drug: Divaza preparation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divaza preparation, 12-week treatment course
Trial: 16724578
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (soft gelatin capsules containing a new self-nanoemulsifying formulation of cyclosporin A, 200 mg) after a fat-rich breakfast (Treatment A)
Trial: 16724578
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (Neoral, Novartis AG, Basel, Switzerland, 200 mg) after a fat-rich breakfast (Treatment B)
Trial: 16724578
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (soft gelatin capsules containing a new self-nanoemulsifying formulation of cyclosporin A, 200 mg) after fasting (Treatment C)
Trial: 12774949
Drug: Anticonvulsants (AC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsants (AC Group)
Trial: 12774949
Drug: No anticonvulsants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticonvulsants (No AC Group)
Trial: 4005120
Drug: 10/170 Oros
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10/170 Oros oxprenolol succinate (170 mg, initial release rate 10 mg/h)
Trial: 4005120
Drug: 16/260 Oros
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16/260 Oros oxprenolol succinate (260 mg, initial release rate 16 mg/h)
Trial: 4005120
Drug: Slow Trasicor
RxNorm normalized name: Slow Trasicor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow Trasicor (160 mg once daily)
Trial: 4005120
Drug: Trasicor (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trasicor (80 mg twice daily)
Trial: 30804818
Drug: Mobile app-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile app-based intervention (treatment as usual plus five modules: psychoeducation, recognition of symptoms and prevention of relapses, problem solving, mindfulness, and contact wall)
Trial: 27746007
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and metronidazole for 5 days postoperatively
Trial: 27746007
Drug: Placebo (identical-looking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical-looking drugs)
Trial: 12860216
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 to 80 mg
Trial: 12860216
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 to 40 mg
Trial: 12860216
Drug: atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 10 to 80 mg
Trial: 10651663
Drug: LAM-2 W
RxNorm normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LAM-2 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 500 mg b.d. for 2 weeks)
Trial: 10651663
Drug: LAM-1 W
RxNorm normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LAM-1 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 500 mg b.d. for 1 week and placebo)
Trial: 10651663
Drug: LA-2 W
RxNorm normalized name: Aminobenzoic Acid/Ascorbic Acid/Beta Carotene/Bioflavonoid/Biotin/Boron/Calcium/Calcium Pantothenate/Choline/Chromium/Copper/Cyanocobalamin/Folic Acid/Hesperidin/Inositol/Iodine/Iron/Magnesium/Manganese/Molybdenum/Niacin/Phytonadione/Potassium/Pyridoxine/Riboflavin/Rutin/Selenium/Silicon/Thiamine/Vanadium/Vitamin A/Vitamin D/Vitamin E/Zinc 8 MG-100 MG-5000 IU-10 MG-0.3 MG-1 MG-100 MG-25 MG-10 MG-0.2 MG-2 MG-0.025 MG-0.4 MG-10 MG-10 MG-0.1 MG-20 MG-100 MG-6 MG-0.1 MG-25 MG-0.07 MG-25 MG-25 MG-15 MG-10 MG-0.025 MG-2.4 MG-15 MG-0.025 MG-5000 IU-400 IU-30 IU-30 MG Oral Tablet [TOTAL FORMULA-2 W/IRON]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA-2 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d. and placebo for 2 weeks)
Trial: 6384452
Drug: Furosemide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (1 mg/kg/day intravenously for three doses)
Trial: 31832291
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg twice daily orally
Trial: 24595923
Drug: Bevacizumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (100 mg, intranasal submucosal injection, 10 mL)
Trial: 17223475
Drug: Pulses of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulses of vincristine (1.5 mg/m2 weekly for 2 weeks) and dexamethasone (6 mg/m2 daily for 7 days) every 10 weeks for six cycles
Trial: 17223475
Drug: Conventional mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional mercaptopurine and methotrexate chemotherapy only
Trial: 11583749
Drug: peginterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2b 1.5 microg/kg each week plus 800 mg/day ribavirin
Trial: 11557910
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg)
Trial: 26273747
Drug: Levobupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine plus dexmedetomidine (20 μg)
Trial: 17332177
Drug: Measles-mumps-rubella vaccine
RxNorm normalized name: MEASLES/MUMPS/RUBELLA VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles-mumps-rubella vaccine
Trial: 17332177
Drug: Mumps vaccine
RxNorm normalized name: Mumps vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mumps vaccine
Trial: 17332177
Drug: Rubella vaccine
RxNorm normalized name: Rubella vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubella vaccine
Trial: 11498212
Drug: Cilomilast 15
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilomilast 15 mg twice daily
Trial: 11498212
Drug: Cilomilast 5
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilomilast 5 mg and 10 mg
Trial: 27500370
Drug: Aqueous solutions
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solutions of surfactants (anionic, non-ionic, amphoteric)
Trial: 25930115
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine ointment (PIO) applied starting on post-vaccination day 7
Trial: 25930115
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine ointment (PIO)
Trial: 25930115
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine ointment (PIO) and control group
Trial: 23220343
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention program (3-month duration including 8 weeks of exercise training, health education, home hazards evaluation/modification, medication review, and specialty consults)
Trial: 21241789
Drug: Controlled-release microparticles
RxNorm normalized name: Microparticulate beta-(1,3)(1,6) glucan from saccharomyces cerevisiae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release microparticles F-3 (TmH:EC ratio 1:2)
Trial: 21241789
Drug: Controlled-release microparticles
RxNorm normalized name: Microparticulate beta-(1,3)(1,6) glucan from saccharomyces cerevisiae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release microparticles F-4 (TmH:EC ratio 1:3)
Trial: 21241789
Drug: Immediate-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release formulation (control)
Trial: 12970142
Drug: Protein and
RxNorm normalized name: Protein and/or protein derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein and energy dense supplement enriched with n‐3 fatty acids and antioxidants (E)
Trial: 12970142
Drug: Isocaloric isonitrogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric isonitrogenous control supplement (C)
Trial: 9515594
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (i.v.IG) 1 g/kg body weight
Trial: 9515594
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous human serum albumin)
Trial: 9515594
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (i.v.IG)
Trial: 8036475
Drug: loracarbef (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loracarbef (200 mg b.i.d. for 7 days)
Trial: 8036475
Drug: amoxicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxicillin (500 mg t.i.d. for 7 days)